The top analyst upgrades, downgrades and other research calls from Friday include Analog Devices, Camping World, Ciena, Deere, RSP Permian, Ulta Beauty and Yum China.
In Wednesday’s session the markets were largely negative with major money center banks leading the charge down, other investment houses were negative as well. Although crude oil pushed much lower, not all…
Chris Lange Jefferies analysts remain reasonably bullish, and in their top growth picks for the week the firm focuses on some stocks that could be top momentum stories for the second quarter.
Lee Jackson The first quarter's top-performing stocks in the S&P 500 index included two pharmaceutical firms, an electricity generator, a video game maker and a media company.
March 29, 2017: The S&P 500 closed higher on the day, up 0.11 % and 2.56 points to 2,361.14. Separately the DJIA closed down 0.20% on the day at 20,659.39, down approximately…
Vertex Pharmaceuticals shares were jumping after the firm released results from two Phase 3 studies in the treatment of cystic fibrosis in ages 12 and older.
Chris Lange A few biopharma stocks made massive runs on Tuesday morning as the result of clinical trial results and earnings. Although not all of these moves were positive the overall sentiment was positive.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Wednesday include Boeing, Capital One, CenturyLink, Morgan Stanley, NRG Energy and Vertex Pharmaceuticals.
The top analyst upgrades, downgrades and initiations seen on Friday include Adobe Systems, Barclays, Dean Foods, Netflix, Simon Property, Snap and Vertex Pharmaceuticals.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Mobileye, Occidental Petroleum, Oracle, Walt Disney, Wal-Mart.
Markets may be slowing down and taking a step back after hitting new highs in what has been known as the Trump rally. Still, a few stocks in the health care sector…
Chris Lange A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding the table, they are cautiously optimistic.
Thursday’s top analyst upgrades, downgrades and initiations include Advanced Micro Devices, Comerica, General Mills, Mastercard and Vertex Pharmaceuticals.
